Explore
Validate
Learn500-P109-100UG
antibody from Invitrogen Antibodies
Targeting: CCL21
6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P109-100UG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CCL21 Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: discontinued.
- Concentration
- 0.1-1.0 mg/mL
Submitted references Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.
The three-dimensional structure of human splenic white pulp compartments.
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages.
Weitzenfeld P, Kossover O, Körner C, Meshel T, Wiemann S, Seliktar D, Legler DF, Ben-Baruch A
Journal of leukocyte biology 2016 Jun;99(6):1009-25
Journal of leukocyte biology 2016 Jun;99(6):1009-25
The three-dimensional structure of human splenic white pulp compartments.
Steiniger B, Rüttinger L, Barth PJ
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2003 May;51(5):655-64
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2003 May;51(5):655-64
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages.
Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D
The Journal of experimental medicine 2001 Sep 17;194(6):797-808
The Journal of experimental medicine 2001 Sep 17;194(6):797-808
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human Exodus-2 (CCL21) by Western Blot analysis CCL21 Polyclonal Antibody (Product # 500-P109-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human Exodus-2 (CCL21) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human Exodus-2 (CCL21) by Western Blot analysis CCL21 Polyclonal Antibody (Product # 500-P109-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human Exodus-2 (CCL21) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human Exodus-2 (CCL21) by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of CCL21 Polyclonal Antibody (Product # 500-P109-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech CCL21 Polyclonal Antibody, Biotin (Product # 500-P109BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human Exodus-2 (CCL21).
